← Back to Clinical Trials
Recruiting NCT05460975

NCT05460975 Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05460975
Status Recruiting
Phase
Sponsor Seoul National University Hospital
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 16,164 participants
Start Date 2022-11-01
Primary Completion 2026-03-30

Eligibility & Interventions

Sex Female only
Min Age 40 Years
Max Age 69 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 16,164 participants in total. It began in 2022-11-01 with a primary completion date of 2026-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

An international multicenter study to prospectively validate the association between sonographic GTC and subsequent breast cancer risk in women with dense breasts.

Eligibility Criteria

Inclusion Criteria 1. be ≥ 40 and \<70 years old at time of US 2. No history of previous breast cancer including DCIS 3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2) 4. undergoing screening breast US using either automated or handheld device Exclusion Criteria 1. history of bilateral prophylactic mastectomy 2. history of bilateral foreign body injection 3. history of bilateral breast implants 4. history of bilateral breast reduction surgery or surgical excision 5. currently pregnant or breast feeding in the preceding 6 months 6. Known distant metastasis from other primary cancer

Contact & Investigator

Central Contact

Woo Kyung Moon, MD, PhD

✉ moonwk1963@gmail.com

📞 +82220722584

Principal Investigator

Woo Kyung Moon, MD, PhD

PRINCIPAL INVESTIGATOR

Seoul National University Hospital

Frequently Asked Questions

Who can join the NCT05460975 clinical trial?

This trial is open to female participants only, aged 40 Years or older, up to 69 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05460975 currently recruiting?

Yes, NCT05460975 is actively recruiting participants. Contact the research team at moonwk1963@gmail.com for enrollment information.

Where is the NCT05460975 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT05460975 clinical trial?

NCT05460975 is sponsored by Seoul National University Hospital. The principal investigator is Woo Kyung Moon, MD, PhD at Seoul National University Hospital. The trial plans to enroll 16,164 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology